371 related articles for article (PubMed ID: 26147622)
1. In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.
Anderson BR; Howell DN; Soldano K; Garrett ME; Katsanis N; Telen MJ; Davis EE; Ashley-Koch AE
PLoS Genet; 2015 Jul; 11(7):e1005349. PubMed ID: 26147622
[TBL] [Abstract][Full Text] [Related]
2. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.
Tzur S; Rosset S; Shemer R; Yudkovsky G; Selig S; Tarekegn A; Bekele E; Bradman N; Wasser WG; Behar DM; Skorecki K
Hum Genet; 2010 Sep; 128(3):345-50. PubMed ID: 20635188
[TBL] [Abstract][Full Text] [Related]
3. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
[TBL] [Abstract][Full Text] [Related]
4. MYH9 and APOL1 are both associated with sickle cell disease nephropathy.
Ashley-Koch AE; Okocha EC; Garrett ME; Soldano K; De Castro LM; Jonassaint JC; Orringer EP; Eckman JR; Telen MJ
Br J Haematol; 2011 Nov; 155(3):386-94. PubMed ID: 21910715
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.
Lipkowitz MS; Freedman BI; Langefeld CD; Comeau ME; Bowden DW; Kao WH; Astor BC; Bottinger EP; Iyengar SK; Klotman PE; Freedman RG; Zhang W; Parekh RS; Choi MJ; Nelson GW; Winkler CA; Kopp JB;
Kidney Int; 2013 Jan; 83(1):114-20. PubMed ID: 22832513
[TBL] [Abstract][Full Text] [Related]
6. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in APOL1 and MYH9 genes is associated with chronic kidney disease among Nigerians.
Tayo BO; Kramer H; Salako BL; Gottesman O; McKenzie CA; Ogunniyi A; Bottinger EP; Cooper RS
Int Urol Nephrol; 2013 Apr; 45(2):485-94. PubMed ID: 22956460
[TBL] [Abstract][Full Text] [Related]
8. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.
Freedman BI; Kopp JB; Langefeld CD; Genovese G; Friedman DJ; Nelson GW; Winkler CA; Bowden DW; Pollak MR
J Am Soc Nephrol; 2010 Sep; 21(9):1422-6. PubMed ID: 20688934
[TBL] [Abstract][Full Text] [Related]
9. Target organ damage in African American hypertension: role of APOL1.
Freedman BI; Murea M
Curr Hypertens Rep; 2012 Feb; 14(1):21-8. PubMed ID: 22068337
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
11. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
Kormann R; Jannot AS; Narjoz C; Ribeil JA; Manceau S; Delville M; Joste V; Prié D; Pouchot J; Thervet E; Courbebaisse M; Arlet JB
Br J Haematol; 2017 Oct; 179(2):323-335. PubMed ID: 28699644
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
Freedman BI; Langefeld CD; Lu L; Divers J; Comeau ME; Kopp JB; Winkler CA; Nelson GW; Johnson RC; Palmer ND; Hicks PJ; Bostrom MA; Cooke JN; McDonough CW; Bowden DW
PLoS Genet; 2011 Jun; 7(6):e1002150. PubMed ID: 21698141
[TBL] [Abstract][Full Text] [Related]
13. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
[TBL] [Abstract][Full Text] [Related]
14. Copy Number Variation at the APOL1 Locus.
Ruchi R; Genovese G; Lee J; Charoonratana VT; Bernhardy AJ; Alper SL; Kopp JB; Thadhani R; Friedman DJ; Pollak MR
PLoS One; 2015; 10(5):e0125410. PubMed ID: 25933006
[TBL] [Abstract][Full Text] [Related]
15. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
[TBL] [Abstract][Full Text] [Related]
16. MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population.
Colares VS; Titan SM; Pereira Ada C; Malafronte P; Cardena MM; Santos S; Santos PC; Fridman C; Barros RT; Woronik V
PLoS One; 2014; 9(3):e87716. PubMed ID: 24658608
[TBL] [Abstract][Full Text] [Related]
17. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.
Kasembeli AN; Duarte R; Ramsay M; Mosiane P; Dickens C; Dix-Peek T; Limou S; Sezgin E; Nelson GW; Fogo AB; Goetsch S; Kopp JB; Winkler CA; Naicker S
J Am Soc Nephrol; 2015 Nov; 26(11):2882-90. PubMed ID: 25788523
[TBL] [Abstract][Full Text] [Related]
18. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
[TBL] [Abstract][Full Text] [Related]
19. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.
Lin CP; Adrianto I; Lessard CJ; Kelly JA; Kaufman KM; Guthridge JM; Freedman BI; Anaya JM; Alarcón-Riquelme ME; ; Pons-Estel BA; Martin J; Glenn S; Adler A; Bae SC; Park SY; Bang SY; Song YW; Boackle SA; Brown EE; Edberg JC; Alarcón GS; Petri MA; Criswell LA; Ramsey-Goldman R; Reveille JD; Vila LM; Gilkeson GS; Kamen DL; Ziegler J; Jacob CO; Rasmussen A; James JA; Kimberly RP; Merrill JT; Niewold TB; Scofield RH; Stevens AM; Tsao BP; Vyse TJ; Langefeld CD; Moser KL; Harley JB; Gaffney PM; Montgomery CG
Genes Immun; 2012 Apr; 13(3):232-8. PubMed ID: 22189356
[TBL] [Abstract][Full Text] [Related]
20. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
